Literature DB >> 15019924

Predicting resectability of periampullary cancer with three-dimensional computed tomography.

Michael G House1, Charles J Yeo, John L Cameron, Kurt A Campbell, Richard D Schulick, Steven D Leach, Ralph H Hruban, Karen M Horton, Elliot K Fishman, Keith D Lillemoe.   

Abstract

The radiographic assessment of extent of tumor burden and local vascular invasion appears to be enhanced with three-dimensional computed tomography (3D-CT). The purpose of this study was to evaluate the impact of preoperative 3D-CT in determining the resectability of patients with periampullary tumors. Intraoperative findings from exploratory laparotomy were gathered prospectively from 140 patients who were thought to have periampullary tumors and were deemed resectable after undergoing preoperative 3D-CT imaging. CT findings were compared to intraoperative findings, and the accuracy of 3D-CT in predicting tumor resectability and, ultimately, the likelihood of obtaining a margin-negative resection were assessed. Of the 140 patients who were thought to have resectable periampullary tumors after preoperative 3D-CT, 115 (82%) were subsequently determined to have periampullary cancer. The remaining 25 patients had benign disease. Among the patients with periampullary cancer, the extent of local tumor burden involving the pancreas and peripancreatic tissues was accurately depicted by 3D-CT in 93% of the patients. 3D-CT was 95% accurate in determining cancer invasion of the superior mesenteric vessels. Preoperative 3D-CT accurately predicted periampullary cancer resectability and a margin-negative resection in 98% and 86% of patients, respectively. For patients with pancreatic adenocarcinoma (n=85), preoperative 3D-CT resulted in a resectability rate and a margin-negative resection rate of 79% and 73%, respectively. The ability of 3D-CT to predict a margin-negative resection for periampullary cancer, including pancreatic adenocarcinoma, relies on its enhanced assessment of the extent of local tumor burden and involvement of the mesenteric vascular anatomy.

Entities:  

Mesh:

Year:  2004        PMID: 15019924     DOI: 10.1016/j.gassur.2003.12.011

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  25 in total

1.  Arterial versus portal venous helical CT for revealing pancreatic adenocarcinoma: conspicuity of tumor and critical vascular anatomy.

Authors:  O Graf; G W Boland; A L Warshaw; C Fernandez-del-Castillo; P F Hahn; P R Mueller
Journal:  AJR Am J Roentgenol       Date:  1997-07       Impact factor: 3.959

Review 2.  Pancreatic carcinoma.

Authors:  A L Warshaw; C Fernández-del Castillo
Journal:  N Engl J Med       Date:  1992-02-13       Impact factor: 91.245

3.  Three-dimensional CT angiography of pancreatic carcinoma: role in staging extent of disease.

Authors:  S L Novick; E K Fishman
Journal:  AJR Am J Roentgenol       Date:  1998-01       Impact factor: 3.959

4.  The surgical treatment of pancreatic carcinoma.

Authors:  M Trede
Journal:  Surgery       Date:  1985-01       Impact factor: 3.982

5.  Spiral-CT in diagnosis of vascular involvement in pancreatic cancer.

Authors:  J Gmeinwieser; S Feuerbach; W Hohenberger; H Albrich; M Strotzer; F Hofstädter; A Geissler
Journal:  Hepatogastroenterology       Date:  1995 Jul-Aug

6.  Pancreatic cancer: value of dual-phase helical CT in assessing resectability.

Authors:  S J Diehl; K J Lehmann; M Sadick; R Lachmann; M Georgi
Journal:  Radiology       Date:  1998-02       Impact factor: 11.105

7.  Ultrafast magnetic resonance imaging improves the staging of pancreatic tumors.

Authors:  M Trede; B Rumstadt; K Wendl; J Gaa; K Tesdal; K J Lehmann; H J Meier-Willersen; P Pescatore; J Schmoll
Journal:  Ann Surg       Date:  1997-10       Impact factor: 12.969

8.  Low mortality following resection for pancreatic and periampullary tumours in 1026 patients: UK survey of specialist pancreatic units. UK Pancreatic Cancer Group.

Authors:  J P Neoptolemos; R C Russell; S Bramhall; B Theis
Journal:  Br J Surg       Date:  1997-10       Impact factor: 6.939

9.  Current status of surgical palliation of periampullary carcinoma.

Authors:  K D Lillemoe; P K Sauter; H A Pitt; C J Yeo; J L Cameron
Journal:  Surg Gynecol Obstet       Date:  1993-01

10.  Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms.

Authors:  G M Fuhrman; C Charnsangavej; J L Abbruzzese; K R Cleary; R G Martin; C J Fenoglio; D B Evans
Journal:  Am J Surg       Date:  1994-01       Impact factor: 2.565

View more
  35 in total

1.  An MRI-driven practice: a new perspective on MRI for the evaluation of adenocarcinoma of the head of the pancreas.

Authors:  Elliot B Tapper; Diego Martin; N Volkan Adsay; David Kooby; Bobby Kalb; Juan M Sarmiento
Journal:  J Gastrointest Surg       Date:  2010-05-14       Impact factor: 3.452

2.  Pancreatic adenocarcinoma.

Authors:  Margaret A Tempero; J Pablo Arnoletti; Stephen Behrman; Edgar Ben-Josef; Al B Benson; Jordan D Berlin; John L Cameron; Ephraim S Casper; Steven J Cohen; Michelle Duff; Joshua D I Ellenhorn; William G Hawkins; John P Hoffman; Boris W Kuvshinoff; Mokenge P Malafa; Peter Muscarella; Eric K Nakakura; Aaron R Sasson; Sarah P Thayer; Douglas S Tyler; Robert S Warren; Samuel Whiting; Christopher Willett; Robert A Wolff
Journal:  J Natl Compr Canc Netw       Date:  2010-09       Impact factor: 11.908

3.  Factors influencing survival in patients undergoing palliative bypass for pancreatic adenocarcinoma.

Authors:  Phillip J Gray; Jingya Wang; Timothy M Pawlik; Barish H Edil; Richard Schulick; Ralph H Hruban; Harry Dao; John Cameron; Christopher Wolfgang; Joseph M Herman
Journal:  J Surg Oncol       Date:  2012-02-03       Impact factor: 3.454

Review 4.  The role of neoadjuvant therapy in pancreatic cancer: a review.

Authors:  Suzanne Russo; John Ammori; Jennifer Eads; Jennifer Dorth
Journal:  Future Oncol       Date:  2016-02-01       Impact factor: 3.404

5.  CLIP method (preoperative CT image-assessed ligation of inferior pancreaticoduodenal artery) reduces intraoperative bleeding during pancreaticoduodenectomy.

Authors:  Manabu Kawai; Masaji Tani; Shinomi Ina; Seiko Hirono; Ryohei Nishioka; Motoki Miyazawa; Kazuhisa Uchiyama; Tetsuya Shimamoto; Hiroki Yamaue
Journal:  World J Surg       Date:  2008-01       Impact factor: 3.352

6.  Computed tomography-based diagnostics might be insufficient in the determination of pancreatic cancer unresectability.

Authors:  Vyacheslav I Egorov; Roman V Petrov; Elena N Solodinina; Gregory G Karmazanovsky; Natalia S Starostina; Natalia A Kuruschkina
Journal:  World J Gastrointest Surg       Date:  2013-04-27

7.  A tumour score with multidetector spiral CT for venous infiltration in pancreatic cancer: influence on borderline resectable.

Authors:  Tiziana Marinelli; Antonella Filippone; Francesca Tavano; Andrea Fontana; Fabio Pellegrini; Jörg Köninger; Götz M Richter; Lorenzo Bonomo; Markus W Büchler; Pierluigi di Sebastiano; Francesco F di Mola
Journal:  Radiol Med       Date:  2014-03-12       Impact factor: 3.469

8.  Resection of the celiac axis for invasive pancreatic cancer.

Authors:  Martin A Makary; Elliot K Fishman; John L Cameron
Journal:  J Gastrointest Surg       Date:  2005-04       Impact factor: 3.452

9.  Relationship between nuclear morphometry, DNA content and resectability of pancreatic cancer.

Authors:  Yin-Cheng He; Wei Peng; Jian-Guo Qiao; Jun Cao; Ji-Wei Chen
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

10.  Comparison of conventional and 3-dimensional computed tomography against histopathologic examination in determining pancreatic adenocarcinoma tumor size: implications for radiation therapy planning.

Authors:  Haoming Qiu; Aaron T Wild; Hao Wang; Elliot K Fishman; Ralph H Hruban; Daniel A Laheru; Rachit Kumar; Amy Hacker-Prietz; Richard Tuli; Erik Tryggestad; Richard D Schulick; John L Cameron; Barish H Edil; Timothy M Pawlik; Christopher L Wolfgang; Joseph M Herman
Journal:  Radiother Oncol       Date:  2012-08-08       Impact factor: 6.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.